Skip to main content

Table 2 Correlation of clinical features, disease characteristics, treatment, and disease status

From: Vulvar cancer: surgical management and survival trends in a low resource setting

Sl no. Age (years) Tumor location Tumor size Histology Chemo/radiotherapy/def Surgery Stage Lymph node Disease status F/U time (m)
1 42 U/L (R) 0.5 × 0.5 MM(AM) ACRT MRV+B/L
IFLND
pT3N1M0(IVA) 3/28 RD 3
2 60 U/L (R) 0.5 × 0.5 SCC(WD) ACRT WLE+B/L
IFLND
FIGO IIIB 7/22 RD 4
34 43 B/L 6.5 × 5.0 SCC(MD) ACRT WLE+B/L
IFLND
FIGO IIIB 6/24 RD 3
38 U/L (L) 5.0 × 3.5 SCC(MD) ART WLE+B/L
IFLND+Recon*
FIGO IB 0/13 NED 23
5 40 B/L 0.5 × 0.5 SCC(MD) NACRT WLE+B/L
IFLND
FIGO IIIB 1/7 NED 12
6 75 U/L (R) 2.5 × 2.5 SCC(PD) ACRT WLE+B/L
IFLND
FIGO II 0/8 NED 18
7 75 U/L (L) 6.5 × 4.0 SCC(WD) Def WLE+B/L
IFLND
FIGO IIIB 9/16 NED 3
8 60 U/L (L) 1.5 × 1.0 SCC(MD) Def RV+B/L (IFLND + PLND)+Recon# FIGO IIIA 2/20 NED 2
9 57 U/L (R) 5.0 × 3.0 SCC(WD)   WLE+B/L
IFLND
FIGO 1B 0/21 NED 59
10 66 U/L (L) 4.5 × 4.5 SCC(WD) NWA Palliative
RV
FIGO IIIB 1/20 RD 2
11 44 B/L 6.5 × 6.0 SCC(MD) Def WLE+B/L
IFLND
FIGO IIIA 0/13 NED 4
12 84 U/L (L) 5.0 × 4.0 SCC(MD) ACRT WLE+B/L
IFLND
FIGO IB 2/18 NED 1
13 56 U/L (R) 3.5 × 2.0 SCC(MD) NWA WLE+B/L
IFLND
FIGO IIIB 2/31 NED 30
14 64 U/L (R) 3.5 × 3.0 AS (MD) NWA RV + B/L (IFLND+PLND) FIGO IIIB 1/17 NED 18
15 50 U/L (L) 1.5 × 1.0 MM(NM) AC RV+ MRH +B/L (IFLND+PLND) pT3N1M0
(IVA)
0/12 RD 2
16 52 U/L (R) 4.0 × 2.0 SCC (MD) +VIN III   WLE+B/L
IFLND
FIGO IA 9/17 NED 12
17 58 U/L (R) 2.0 × 1.5 SCC(MD) ART WLE+B/L
IFLND
FIGO IIIC 0/9 NED 8
18 41 U/L (L) 3.0 × 1.5 SCC(WD) ART WLE+B/L
IFLND
FIGO IB 0/12 NED 7
19 65 U/L (R) 2.0 × 1.0 SCC(MD) ACRT WLE+ I/L
IFLND
FIGO IB 0/13 NED 6
20 44 U/L (R) 3.0 × 2.0 SCC(MD) ACRT WLE+B/L
IFLND
FIGO IIIB 4/14 R 5
  1. Abbreviations: U/L unilateral, B/L bilateral, L left, R right, SCC squamous cell carcinoma, MM malignant melanoma, NM nodular melanoma, AM amelanotic melanoma, AS adenosquamous cell carcinoma, WD well-differentiated, MD moderately differentiated, PD poorly differentiated, VIN vulvar intraepithelial neoplasia, ART adjuvant radiotherapy, ACRT adjuvant chemoradiotherapy, Def defaulted case, NWA not willing for adjuvant treatment, Pall Chemo palliative chemotherapy, WLE wide local excision, RV radical vulvectomy, MRV modified radical vulvectomy, MRH modified radical hysterectomy, IFLND inguinofemoral lymph node dissection, PLND pelvic lymph node dissection, NED no evidence of disease, RD recurrent disease, m month, FIGO International Federation of Gynaecology and Obstetrics, Recon reconstruction
  2. *Reconstruction by V-Y gracilis advancement flap
  3. #Reconstruction by local rotation advancement V-Y fasciocutaneous flap